Posts by: Margarida Azevedo, MSc

Margarida Azevedo, MSc

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

January 29, 2018

Pandion Obtains $58 Million to Keep Developing Autoimmune and Bowel Disease Therapies

News

Pandion Therapeutics has obtained $58 million in financing to continue developing treatments for autoimmune and inflammatory diseases, including bowel disorders. Polaris Partners, Versant Ventures and Roche Venture Fund led the financing round. ... Read more

January 24, 2018

U.S. Survey Sheds Light on How Ulcerative Colitis Affects Patients’ Lives

News

Two-thirds of ulcerative colitis patients believe the disease affects their personal relationships and half think it impacts their ability to obtain an education or their career, a U.S. survey shows. The UC ... Read more

January 22, 2018January 22, 2018

Lyfebulb, UnitedHealth Launch ‘Innovation Challenge’ Contest to Fight IBD

News

Lyfebulb and UnitedHealth Group will jointly launch an innovation challenge for new business and product ideas targeting inflammatory bowel disease (IBD). The challenge, to take place later this year, is ... Read more

January 15, 2018

FDA OKs Application for Immunic’s UC Therapy, Green-lighting Phase 2 Trial

News

The U.S. Food and Drug Administration has cleared the way for Immunic Therapeutics to begin a Phase 2 trial testing IMU-838, its therapy candidate for ulcerative colitis. The FDA’s approval of Immunic’s investigational new drug ... Read more

January 9, 2018January 9, 2018

FDA Clears First Fully Automated Calprotectin Test for IBD Diagnosis, Inova Says

News

The U.S. Food and Drug Administration (FDA) has approved the QUANTA Flash Calprotectin test to help diagnose inflammatory bowel disease (IBD) and differentiate that disease from irritable bowel syndrome (IBS). Developed by ... Read more

January 5, 2018

Palatin to Start Clinical Trials of Ulcerative Colitis Therapy After FDA Sign-off

News

Palatin Technologies plans to start clinical trials of its ulcerative colitis therapy PL-8177 in the next three months. The U.S. Food and Drug Administration’s decision to accept Palatin’s Investigational New Drug application for the treatment opened ... Read more

December 22, 2017December 22, 2017

Ionis Brings Treatment for Gastrointestinal Immune Disorders to Clinical-trial Stage

News

Janssen Biotech plans a Phase 1 clinical trial of a therapy that its partner Ionis Pharmaceuticals developed as a treatment for gastrointestinal immune disorders. Under their collaboration agreement, Ionis received $5 million for bringing ... Read more

December 20, 2017

Alofisel for Crohn’s Fistulas Receives EMA Recommendation for Marketing Authorization in EU

News

TiGenix received a European Medicines Agency (EMA) recommendation for the marketing authorization of Alofisel (darvadstrocel, Cx601) as an advanced therapy medicinal product (ATMP) for the treatment of complex perianal fistulas in people with ... Read more

December 15, 2017

Vedanta Granted Four U.S. Patents for Therapeutics Based on Beneficial Gut Bacteria

News

Vedanta Biosciences has recently been granted four U.S. patents covering pharmaceutical compositions of therapeutics targeting inflammatory bowel disease (IBD) and other immune-mediated and infectious conditions. The new patents protect Vedanta’s therapeutic ... Read more

December 7, 2017

#InTheirShoes Campaign Lets Healthy Canadians Experience What It’s Like Living with IBD

News

Fifteen Canadians with connections to inflammatory bowel disease marked Crohn’s and Colitis Awareness Month by taking part in a two-day simulation of what it’s like to live with IBD. The campaign, which involved overcoming ... Read more